Kailera Therapeutics has reported positive topline results from two Phase 3 trials conducted in China by Hengrui Pharma for HRS-7535, an oral small-molecule glucagon-like peptide-1 receptor agonist that Kailera is developing outside Greater China as KAI-7535.
In the HARBOR-1 obesity trial, the highest dose produced mean weight loss of 10.9% at Week 44 and 11.1% at Week 50 among participants who remained on treatment without using another weight-loss therapy. In the OUTSTAND-2 type 2 diabetes trial, all three tested doses met the primary endpoint of non-inferiority to dapagliflozin, with average haemoglobin A1c reductions ranging from 1.50% to 1.68%.
The July 7 results strengthen the evidence that a once-daily oral small molecule can deliver clinically meaningful metabolic effects without the manufacturing and administration requirements of an injectable peptide. They also expose an important tolerability challenge, with nausea reported in about 70% of obesity-trial participants receiving KAI-7535 and vomiting reported in approximately two-thirds.
Kailera is not treating the Chinese Phase 3 results as a substitute for global development. The company has already started a separate 320-patient Phase 2 obesity study in the United States and Australia using a lower starting dose and slower titration schedule intended to improve the balance between weight loss and gastrointestinal tolerability.
How much weight loss did KAI-7535 produce in the HARBOR-1 Phase 3 obesity trial?
HARBOR-1 enrolled 556 adults with obesity or overweight in China. Participants had an average baseline body weight of 94.1 kilograms and an average body mass index of 34.0 kilograms per square metre. Approximately 62% of the participants were women.
Participants were assigned to receive once-daily HRS-7535 at 120 mg, HRS-7535 at 180 mg or placebo. At Week 44, the efficacy analysis showed average weight reductions of 9.5% with the 120 mg dose and 10.9% with the 180 mg dose, compared with 2.5% for placebo.
The treatment-policy analysis, which more closely reflects outcomes regardless of treatment discontinuation or other events, showed weight loss of 8.0% and 9.8% for the two active doses, compared with 2.4% for placebo.
At Week 50, an additional analysis showed mean weight loss of 9.5% with 120 mg and 11.1% with 180 mg, compared with 2.6% for placebo among participants included in the efficacy estimand.
The results demonstrate clear drug activity, but they do not place KAI-7535 at the top of the obesity efficacy range. Kailera’s commercial argument is likely to depend on convenience, manufacturing scalability, access and acceptable long-term tolerability rather than claiming the greatest weight reduction in the market.
Did enough patients achieve clinically meaningful weight-loss thresholds?
The proportion of participants reaching standard weight-loss thresholds provides a more practical view than the group average alone.
At Week 44, 58.6% of participants receiving 120 mg and 68.2% receiving 180 mg achieved at least 5% weight loss. Approximately 39.6% and 46.6%, respectively, achieved at least 10% weight loss.
At least 15% weight loss was achieved by 18.5% of participants receiving 120 mg and 26.0% receiving 180 mg. These results indicate that a meaningful minority experienced weight reduction approaching the range associated with larger improvements in metabolic risk.
The variability also matters. Most participants did not reach the 15% threshold, meaning clinicians and payers would need to understand which patients are most likely to benefit and when treatment should be changed if weight loss remains limited.
Future studies should examine whether response can be predicted through baseline body mass index, diabetes status, drug exposure, adherence or early weight-loss patterns.
Why are the high nausea and vomiting rates the biggest concern in the obesity data?
Most treatment-emergent adverse events were described as mild or moderate and related to the gastrointestinal system. That pattern is consistent with the wider glucagon-like peptide-1 class, but the frequency reported in HARBOR-1 was high.
Nausea occurred in 70.3% of participants receiving 120 mg and 70.0% receiving 180 mg, compared with 16.2% for placebo. Vomiting occurred in 66.7% and 68.6% of participants in the active groups, compared with 4.5% for placebo.
Diarrhoea was reported in 36.9% of the 120 mg group and 35.9% of the 180 mg group, compared with 15.3% for placebo.
The discontinuation rates attributed to adverse events were much lower than the raw symptom rates, at 4.1% for 120 mg and 3.1% for 180 mg, compared with 2.7% for placebo. That suggests many events were temporary or manageable, although complete data are needed to understand their duration, severity and relationship to dose escalation.
In a chronic obesity treatment, tolerability affects more than regulatory approval. Frequent nausea or vomiting can reduce adherence, discourage prescribing and weaken real-world persistence even when relatively few clinical-trial participants formally discontinue treatment.
Can Kailera’s slower global titration schedule improve tolerability without sacrificing efficacy?
Kailera began its global Phase 2 KAI-7535 obesity trial in April 2026. The study is expected to enrol approximately 320 adults in the United States and Australia and will evaluate several doses and schedules over 44 weeks.
All active-treatment participants start at 15 mg and increase the dose every four weeks. The programme includes doses reaching 180 mg, while a higher-dose cohort may escalate to 360 mg or remain at the maximum tolerated dose.
The global trial uses a lower starting dose and more gradual titration than the Chinese Phase 3 programme. This is intended to reduce early gastrointestinal symptoms while allowing patients time to adapt before reaching higher exposure.
The company is also evaluating morning and evening dosing. Timing may influence tolerability, eating patterns and treatment adherence, although the study must establish whether any meaningful difference exists.
A slower titration could reduce nausea and vomiting, but it may also delay weight loss or prevent some patients from reaching an effective dose. The key question is whether Kailera can preserve most of the efficacy while materially improving the patient experience.
Why do the Chinese Phase 3 results not automatically establish a global regulatory pathway?
HARBOR-1 provides valuable late-stage evidence, but Kailera is developing KAI-7535 for markets outside China under rights licensed from Hengrui Pharma. Regulators in the United States, Europe and other regions will assess whether the Chinese results are sufficiently applicable to their populations and clinical practices.
Differences in body composition, average body weight, diet, background treatment and genetic factors can affect exposure and response. The HARBOR-1 population had an average body mass index of 34.0, while future global trials may enrol a broader range of patients with higher baseline weights and different comorbidities.
Kailera’s global Phase 2 study is therefore important for dose selection, tolerability and pharmacological bridging. Positive results could support a later global Phase 3 programme designed specifically for international registration.
The company expects the Phase 2 data in 2027. That means KAI-7535 remains several development steps away from possible approval outside Greater China, despite already generating Phase 3 evidence in China.
What did OUTSTAND-2 show in adults with type 2 diabetes?
OUTSTAND-2 enrolled 810 adults with type 2 diabetes that was inadequately controlled despite metformin treatment. Participants had an average baseline haemoglobin A1c level of 8.60%, average body weight of 74.7 kilograms and average body mass index of 27.1.
Participants received once-daily HRS-7535 at 30 mg, 60 mg or 90 mg, or dapagliflozin at 10 mg. The primary endpoint was the change in haemoglobin A1c at Week 32.
Average haemoglobin A1c reductions in the efficacy analysis were 1.58% with 30 mg, 1.50% with 60 mg and 1.68% with 90 mg. Dapagliflozin produced a 1.28% reduction.
All three HRS-7535 doses met the trial’s non-inferiority objective, while the 90 mg dose demonstrated a statistically greater reduction than dapagliflozin.
The study also recorded improvements in body weight, systolic blood pressure, blood lipids and urinary albumin-to-creatinine ratio. Full data will be needed to determine the magnitude and consistency of those secondary effects.
Why is the dapagliflozin comparison clinically relevant but commercially incomplete?
Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor used to lower blood glucose and provide cardiovascular and kidney benefits in appropriate patients. Demonstrating non-inferiority provides a useful active comparison rather than relying only on placebo.
The comparison does not establish that KAI-7535 offers the same cardiovascular or renal protection. Those benefits require dedicated evidence and cannot be inferred solely from haemoglobin A1c, body weight or urinary biomarker changes.
KAI-7535 may eventually be positioned as an additional oral option for patients who need stronger glycaemic control or weight reduction. It may also be used alongside other medicines, depending on safety, labelling and outcomes evidence.
The diabetes market is highly competitive, and glucose lowering alone is no longer sufficient to define a major commercial advantage. Long-term cardiovascular safety, kidney outcomes, weight effects, tolerability, cost and ease of use will all influence adoption.
Does the absence of a liver safety signal remove a major small-molecule GLP-1 risk?
Kailera reported no liver safety signal in either Phase 3 trial, consistent with the earlier HRS-7535 clinical programme. More than 2,000 patients have now received the compound in studies conducted in China.
This is encouraging because small-molecule drug candidates can generate liver toxicity through mechanisms unrelated to their intended target. A liver signal could restrict dosing or end development even when efficacy is strong.
The available result does not eliminate the risk. Regulators will examine laboratory abnormalities, exposure patterns, individual cases and longer treatment periods across the full development database.
Obesity medicines may be used by large populations for years, making uncommon adverse events commercially and clinically important. Safety monitoring will therefore continue through global trials and any eventual post-approval studies.
Why are oral small-molecule GLP-1 drugs strategically attractive?
Injectable glucagon-like peptide-1 therapies have transformed obesity and diabetes treatment, but injections remain a barrier for some patients. Manufacturing peptide medicines and filling injection devices can also be complex and capital intensive.
A small-molecule tablet could be easier to manufacture at large scale, distribute through conventional pharmaceutical supply chains and store without the same device requirements as an injectable product.
Oral delivery could broaden treatment among patients who prefer tablets or hesitate to start an injectable therapy. It could also support expansion into healthcare systems where cost, refrigeration and device supply limit access.
The advantage depends on the final product profile. A daily tablet with frequent vomiting may be less attractive than a weekly injection with better tolerability. Oral convenience cannot compensate for weak efficacy or a difficult dosing routine.
KAI-7535 must therefore show that it combines meaningful weight loss with manageable symptoms, predictable absorption and practical administration.
How does KAI-7535 fit within Kailera’s wider obesity pipeline?
KAI-7535 is one of four clinical-stage programmes in Kailera’s obesity portfolio. The lead asset is ribupatide injection, a once-weekly glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor dual agonist already being evaluated in a global Phase 3 programme.
Kailera is also developing an oral formulation of ribupatide and an injectable triple agonist targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon receptors.
The portfolio gives Kailera several opportunities across injectable and oral treatment. It also creates internal competition for capital, clinical resources and commercial positioning.
Oral ribupatide has already shown weight loss of up to 12.1% at 26 weeks in a Chinese Phase 2 study with substantially lower reported vomiting rates than those seen in HARBOR-1. If that profile is reproduced globally, oral ribupatide could become Kailera’s preferred oral candidate.
KAI-7535 could still offer manufacturing or dosing advantages because it is a small molecule rather than an orally delivered peptide. The company will need to determine whether both programmes serve distinct patient segments or whether one ultimately demonstrates a superior benefit-risk profile.
What does Hengrui Pharma gain from the KAI-7535 development strategy?
Hengrui Pharma discovered HRS-7535 and retains rights in China, Hong Kong, Macau and Taiwan. Kailera holds development and commercial rights outside Greater China under a broader metabolic-disease licensing agreement.
This structure allows Hengrui to advance large clinical programmes in China while Kailera finances and conducts development for international markets. Data generated by each company can inform the other’s dose selection, safety monitoring and regulatory strategy.
Hengrui plans to submit marketing applications in China for obesity and type 2 diabetes. Approval there could provide early commercial validation before Kailera completes global development.
The arrangement also illustrates the increasing importance of Chinese pharmaceutical research in the global obesity market. International companies are licensing programmes after substantial clinical work has already been completed, potentially shortening development timelines while accepting the need for global bridging studies.
What financial position does Kailera have to fund global development?
Kailera completed a $718.8 million initial public offering in April 2026 and began trading on the Nasdaq Global Select Market under the ticker KLRA.
The company has indicated that its available cash, including the offering proceeds, should fund operations into the middle of 2028. This provides resources for the KAI-7535 Phase 2 study, ribupatide Phase 3 programme and other pipeline work.
The portfolio remains expensive to develop. Multiple international obesity trials can enrol hundreds or thousands of patients and require long treatment periods, extensive safety monitoring and large-scale manufacturing.
Kailera shares traded near $21.27 during the July 7 session, down approximately 8.7% from the previous close despite the positive efficacy results. The reaction suggests that investors focused on the high gastrointestinal event rates, the time required for global development or expectations that had already been incorporated into the valuation.
What must the full Phase 3 datasets clarify before KAI-7535 can be properly judged?
The topline results provide the primary efficacy findings and selected safety information, but they do not show the complete pattern of response.
Detailed presentations should explain when nausea and vomiting occurred, how long the symptoms lasted and whether they were concentrated during dose escalation. The data should also show dose reductions, temporary interruptions, adherence and the proportion of participants who reached and maintained the target dose.
Weight-loss trajectories will reveal whether the effect had plateaued by Week 44 or was continuing at Week 50. Longer follow-up is needed to assess maintenance, metabolic outcomes and what happens after treatment is stopped.
Subgroup analyses should examine sex, age, baseline body mass index, diabetes status and other factors that could influence efficacy or tolerability. Investigators will also need to disclose serious adverse events, gallbladder complications, pancreatitis assessments and cardiovascular findings.
The complete OUTSTAND-2 dataset should clarify weight loss, kidney markers and hypoglycaemia across doses, as well as whether the 90 mg dose provides a meaningful advantage over lower exposure.
Do the Phase 3 results make KAI-7535 a credible global oral obesity contender?
The HARBOR-1 and OUTSTAND-2 results establish that KAI-7535 is biologically and clinically active. The compound produced double-digit average weight loss at the highest obesity dose and substantial haemoglobin A1c reductions across all diabetes doses.
The evidence also supports the strategic case for oral small-molecule glucagon-like peptide-1 medicines. A scalable tablet could expand access and provide an alternative for patients who do not want injections.
The principal weakness is tolerability. Nausea in about seven out of ten participants and vomiting in roughly two-thirds are difficult figures to ignore, even though formal discontinuation rates were low.
KAI-7535 has become a credible oral metabolic drug candidate, but the Chinese Phase 3 results do not yet establish a globally competitive product profile. Kailera’s slower-titration Phase 2 study must show that gastrointestinal symptoms can be reduced without sacrificing too much weight loss.
If the global programme produces similar efficacy with substantially better tolerability, KAI-7535 could become an important oral option in obesity and potentially type 2 diabetes. If high symptom rates persist, the drug may struggle against weekly injections and other oral programmes offering a more acceptable long-term experience.
The July 7 data therefore answer the question of whether KAI-7535 works. The next trial must answer the more commercially decisive question of whether enough patients can comfortably remain on treatment to make that efficacy matter in routine care.
